Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Stewart

Showing results (161-170 of 208) with videos related to

Pageof 21
Sort By:
Blood Cancer Journal|February 6, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaA Keith Stewart, Amrita Y Krishnan, Seema Singhal, et al.
Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Blood|January 9, 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialA Keith Stewart, Suzanne Trudel, Nizar J Bahlis, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Pageof 21

Showing results (161-170 of 208) with videos related to

Sort By:
Pageof 21
Blood Cancer Journal|February 6, 2019
Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myelomaA Keith Stewart, Amrita Y Krishnan, Seema Singhal, et al.
Blood|April 12, 2012
Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosisAngela Dispenzieri, Francis Buadi, Kristina Laumann, et al.
American Journal of Hematology|June 2, 2011
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trialShaji K Kumar, Martha Q Lacy, Suzanne R Hayman, et al.
Blood|March 28, 2009
Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasonePrashant Kapoor, Shaji Kumar, Rafael Fonseca, et al.
Blood|January 9, 2013
A randomized phase 3 trial of thalidomide and prednisone as maintenance therapy after ASCT in patients with MM with a quality-of-life assessment: the National Cancer Institute of Canada Clinicals Trials Group Myeloma 10 TrialA Keith Stewart, Suzanne Trudel, Nizar J Bahlis, et al.
Blood|June 22, 2011
Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory diseaseMartha Q Lacy, Jacob B Allred, Morie A Gertz, et al.
Cancer Research|April 9, 2009
Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenstrom's macroglobulinemiaEsteban Braggio, Jonathan J Keats, Xavier Leleu, et al.
The Lancet. Haematology|October 10, 2022
Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b-2, open-label studyThomas Martin, Yi Lin, Mounzer Agha, et al.
Blood|October 23, 2013
Smoldering multiple myeloma requiring treatment: time for a new definition?Angela Dispenzieri, A Keith Stewart, Asher Chanan-Khan, et al.
American Journal of Hematology|February 24, 2017
A phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAllison Rosenthal, Amylou C Dueck, Stephen Ansell, et al.
Pageof 21